Speakers - Sachs Associates

CONTACT
Wolfgang Kintzel
Chief Executive Officer
ADDRESS
Gottfried-Hagen-Str. 62
51105 Koeln
Germany
TELEPHONE
+49 221 460208 00
FAX
+49 221 460208 01
EMAIL
kintzel@cevec.com
YEAR FOUNDED
2001
Cevec Pharmaceuticals GmbH
www.cevec.com
FINANCIAL SUMMARY
Since 2009 CEVEC successfully markets its cell based technology for protein and antibody production. The
company has attracted 14 Mio. EUR venture capital in several venture rounds up to now. Lead investors include
Creathor Venture and NRW.Bank
COMPANY PROFILE
The CAP vaccine business case:
CEVEC commercializes an innovative platform technology for the production of vaccines and biopharmaceuticals
in human cell lines.
CEVEC’s CAP cells hold high promise for a best-in-class production system for viral vaccines, such as hCMV,
Influenza and others, as shown by a recent case study. Compared to leading other cellular production systems
(like MDCK) CAP demonstrated outstanding results in view of virus yield, extreme short production cycles and
minimal media consumption. CEVEC’s CAP system is suspension based and serum free offering the best starting
point for new vaccine production approaches with excellent upscaling possibilities. Being the only remaining
independent supplier for human production cell lines, the company sets out to repeat the growth story of Crucell
B.V., recently acquired by Johnson & Johnson for 2.4 Bn US$.
Feasibility studies further demonstrated CAP being a versatile virus production platform with a broad
susceptibility for various human-pathogenic human viruses. Commercially significant targets include hCMV, RSV,
Influenza, Polio, Measles, AAV, Adenoviruses, Lentiviruses and others. Several lead projects have been identified
and planned, including the first human platform for hCMV, together with its partner Vaccine Project Manager,
Hannover, Germany.
CEVEC is underway to close another 7-10 Mio. EUR venture round. This investment will be used to push the
vaccine lead projects, such as hCMV within 3 years to clinical phase I/IIa results and manage a broad roll-out of
its vaccine production technology in order to maximize its company exit value by 2015. Venture investors are still
invited to participate in an exciting low-risk and high return growth story.
MANAGEMENT
Wolfgang Kintzel, CEO
Dr Rainer Lichtenberger, Managing Director, CFO/COO
Dr Gudrun Schiedner, CSO
Dr Nicole Faust, VP Development & Services
Gary Boch, VP BD North America
Dr Hartmut Tintrup, Dir. BD Europe & ROW
t back :: next u
WELCOME PHARMA LICENSING GROUPS
SPEAKERS
PRESENTING COMPANIES SUPPORTING ORGANISATIONS
ORGANISERS